FDA approves Byetta injection for expanded combination use in type II diabetes
Wednesday, December 27, 2006 13:00 IST San Diego, Indianapolis
Amylin Pharmaceuticals Inc. and Eli Lilly and Company announced that the US Food and Drug Administration (FDA) has approved Byetta (exenatide) injection as an add-on therapy to improve blood sugar control in people